KRAS P, G12C MUTATED /ADVANCED METASTATIC NSCLC

Clinical trials for KRAS P, G12C MUTATED /ADVANCED METASTATIC NSCLC explained in plain language.

Never miss a new study

Get alerted when new KRAS P, G12C MUTATED /ADVANCED METASTATIC NSCLC trials appear

Sign up with your email to follow new studies for KRAS P, G12C MUTATED /ADVANCED METASTATIC NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for Tough-to-Treat lung cancer: targeted drug trial shows promise

Disease control Ongoing

This study compares a new targeted drug called AMG 510 against standard chemotherapy (docetaxel) for people with advanced lung cancer that has a specific KRAS mutation and has stopped responding to previous treatments. The trial aims to see if AMG 510 can better control cancer gr…

Matched conditions: KRAS P, G12C MUTATED /ADVANCED METASTATIC NSCLC

Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

KRAS P, G12C MUTATED /ADVANCED METASTATIC NSCLC

Get alerted when new KRAS P, G12C MUTATED /ADVANCED METASTATIC NSCLC trials appear

New hope for Tough-to-Treat lung cancer: targeted drug trial shows promise